Effects of sertraline use on bone microarchitecture: A literature review

Year 2025, Volume: 42 Issue: 3, 324 - 337, 30.09.2025

Büşra Nur Özcan , Ahmet Uzun

Abstract

Selective serotonin reuptake inhibitors (SSRIs), particularly sertraline, are widely prescribed for depression and anxiety disorders. Although primarily targeting the central nervous system, emerging evidence suggests that SSRIs can significantly impact bone health. This narrative review aims to evaluate the clinical effects of long-term SSRI use on bone mineral density (BMD) and fracture risk. A literature review was conducted across PubMed, Scopus, Web of Science, and Google Scholar, covering studies from 1998 to 2025. Results from both preclinical and clinical data consistently demonstrate a reduction in BMD associated with prolonged SSRI exposure, particularly in trabecular-rich anatomical regions such as the femoral neck, vertebrae, and mandible. These changes have been linked to decreased osteoblastic activity and increased bone resorption, leading to structural weakening and elevated fracture risk. Clinical findings suggest that elderly individuals and postmenopausal women are especially vulnerable, and that fracture risk appears to correlate with both the dose and duration of SSRI therapy. While the exact molecular mechanisms remain under investigation, the clinical implications are clear: bone health assessment and monitoring should be integral to the care of patients prescribed SSRIs, particularly those with additional risk factors for osteoporosis. Interventions such as BMD screening, calcium and vitamin D supplementation, and lifestyle modifications may be beneficial in reducing skeletal complications. This review underscores the need for increased clinical awareness and interdisciplinary management strategies to mitigate potential bone-related side effects of SSRI treatment in at-risk populations.

Keywords

Sertraline , Selective Serotonin Reuptake Inhibitors , Bone Mineral Density , Osteoporosis Risk , Fracture , Bone Health Monitoring

Ethical Statement

This study is a literature review and does not involve any human or animal subjects. Therefore, ethical committee approval is not required.

References

• Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (Am Psychiatr Publ). 2018 Oct;16(4):420-9.
• Ortuno MJ, Robinson ST, Subramanyam P, Paone R, Huang YY, Guo XE, et al. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat Med. 2016 Oct;22(10):1170- 9.
• Lavoie B, Lian JB, Mawe GM. Regulation of Bone Metabolism by Serotonin. Adv Exp Med Biol. 2017;1033:35-46. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007 Jun 25;167(12):1240-5.
• Alsugeir D, Adesuyan M, Avgerinou C, Talaulikar V, Wei L, Brauer R. Risk of osteoporotic fractures in menopausal women with common mental health diagnoses prescribed SSRIs/SNRIs: cohort and self-controlled case series analyses. Arch Osteoporos. 2024 Oct 23;19(1):100.
• Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol. 2010 Oct 4;191(1):7-13.
• Bradaschia-Correa V, Josephson AM, Mehta D, Mizrahi M, Neibart SS, Liu C, et al. The Selective Serotonin Reuptake Inhibitor Fluoxetine Directly Inhibits Osteoblast Differentiation and Mineralization During Fracture Healing in Mice. J Bone Miner Res. 2017 Apr;32(4):821-33.
• Fischer V, Bulow JM, Kruger BT, Ragipoglu D, Vikman A, Haffner-Luntzer M, et al. Role of Mast-Cell-Derived RANKL in Ovariectomy-Induced Bone Loss in Mice. Int J Mol Sci. 2023 May 23;24(11).
• Warden SJ, Fuchs RK. Do Selective Serotonin Reuptake Inhibitors (SSRIs) Cause Fractures? Curr Osteoporos Rep. 2016 Oct;14(5):211-8.
• Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62.
• Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998 Dec;12(4):249-71.
• Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008 Nov 28;135(5):825-37.
• Chabbi-Achengli Y, Coman T, Collet C, Callebert J, Corcelli M, Lin H, et al. Serotonin Is Involved in Autoimmune Arthritis through Th17 Immunity and Bone Resorption. Am J Pathol. 2016 Apr;186(4):927-37.
• Howie RN, Herberg S, Durham E, Grey Z, Bennfors G, Elsalanty M, et al. Selective serotonin re-uptake inhibitor sertraline inhibits bone healing in a calvarial defect model. Int J Oral Sci. 2018 Sep 3;10(3):25.
• Malykhin N, Serrano J, Reiz B, Hegadoren K, Pietrasik W, Whittal R. Effects of Variations in Daily Cortisol Pattern and Long-Term Cortisol Output on Hippocampal Subfield Volumes in the Adult Human Brain. Biol Psychiatry Glob Open Sci. 2025 May;5(3):100458.
• Zhou C. Reply to comments on "Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis". Osteoporos Int. 2022 Dec;33(12):2657-8.
• Silverstein-Metzler MG, Justice JN, Appt SE, Groban L, Kitzman DW, Carr JJ, et al. Long-term sertraline treatment and depression effects on carotid artery atherosclerosis in premenopausal female primates. Menopause. 2017 Oct;24(10):1175-84.
• Durham E, Zhang Y, LaRue A, Bradshaw A, Cray J. Selective serotonin reuptake inhibitors (SSRI) affect murine bone lineage cells. Life Sci. 2020 Aug 15;255:117827.
• Inose H. [Control of bone remodeling by nervous system. The role of serotonin in the regulation of bone metabolism]. Clin Calcium. 2010 Dec;20(12):1850-956.
• Fraher D, Hodge JM, Collier FM, McMillan JS, Kennedy RL, Ellis M, et al. Citalopram and sertraline exposure compromises embryonic bone development. Mol Psychiatry. 2016 May;21(5):656-64.
• Lam RW, Wong HK, Kumarsing RA, Chua AN, Ho RC, McIntyre RS, et al. Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression. Transl Psychiatry. 2022 Aug 20;12(1):339.
• Abu Nada L, Al Subaie A, Mansour A, Wu X, Abdallah MN, Al-Waeli H, et al. The antidepressant drug, sertraline, hinders bone healing and osseointegration in rats' tibiae. J Clin Periodontol. 2018 Dec;45(12):1485-97.
• Martin AM, Young RL, Leong L, Rogers GB, Spencer NJ, Jessup CF, et al. The Diverse Metabolic Roles of Peripheral Serotonin. Endocrinology. 2017 May 1;158(5):1049-63.
• Rosenblat JD, Gregory JM, Carvalho AF, McIntyre RS. Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms. Curr Mol Med. 2016;16(2):165-78.
• Yang M, Birnbaum MJ, MacKay CA, Mason-Savas A, Thompson B, Odgren PR. Osteoclast stimulatory transmembrane protein (OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation. J Cell Physiol. 2008 May;215(2):497-505.
• Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013 Feb;123(2):666-81.
• Vestergaard P, Prieto-Alhambra D, Javaid MK, Cooper C. Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int. 2013 Feb;24(2):671-80.
• Tamblyn R, Bates DW, Buckeridge DL, Dixon WG, Girard N, Haas JS, et al. Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication. J Am Geriatr Soc. 2020 Jul;68(7):1494-503.
• Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. Osteoporos Sarcopenia. 2017 Jun;3(2):75-81.
• Ahmed N, Bone JK, Lewis G, Freemantle N, Harmer CJ, Duffy L, et al. The effect of sertraline on emotional processing: secondary analyses of the PANDA randomised controlled trial. Psychol Med. 2022 Oct;52(13):2814-21.
• Hu J, Xie K, Wu S, Chen Y. Osteoporosis and Fracture Risk Associated with Novel Antidepressants: A Systematic Review and Meta-Analysis. Actas Esp Psiquiatr. 2024 Jun;52(3):334-46.
• Saraykar S, John V, Cao B, Hnatow M, Ambrose CG, Rianon N. Association of Selective Serotonin Reuptake Inhibitors and Bone Mineral Density in Elderly Women. J Clin Densitom. 2018 Apr-Jun;21(2):193-9.
• Haddad YK, Luo F, Karani MV, Marcum ZA, Lee R. Psychoactive medication use among older community-dwelling Americans. J Am Pharm Assoc (2003). 2019 Sep-Oct;59(5):686-90.
• Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007 Jun 25;167(12):1246-51.
• F. HM. Vitamin D deficiency. The New England journal of medicine. 2007;357(3):266-81.
• P. L. Vitamin D physiology. Progress in biophysics and molecular biology. 2006;92(1):4-8.
• Agarwal S, Germosen C, Kil N, Bucovsky M, Colon I, Williams J, et al. Current anti-depressant use is associated with cortical bone deficits and reduced physical function in elderly women. Bone. 2020 Nov;140:115552.
• Calarge CA, Ellingrod VL, Zimmerman B, Bliziotes MM, Schlechte JA. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec;72(12):1685-90.
• Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30.
• Vazquez-Lorente H, Garcia-Gavilan JF, Shyam S, Konieczna J, Martinez JA, Martin-Sanchez V, et al. Mediterranean Diet, Physical Activity, and Bone Health in Older Adults: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2025 Apr 1;8(4):e253710.
• Jung YS, Suh D, Choi HS, Park HD, Jung SY, Suh DC. Risk of Fall-Related Injuries Associated with Antidepressant Use in Elderly Patients: A Nationwide Matched Cohort Study. Int J Environ Res Public Health. 2022 Feb 17;19(4).
• Mercurio M, de Filippis R, Spina G, De Fazio P, Segura-Garcia C, Galasso O, et al. The use of antidepressants is linked to bone loss: A systematic review and metanalysis. Orthop Rev (Pavia). 2022;14(6):38564.
• Moura C, Bernatsky S, Abrahamowicz M, Papaioannou A, Bessette L, Adachi J, et al. Antidepressant use and 10- year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int. 2014 May;25(5):1473-81.
• Rajha HE, Abdelaal R, Charfi K, Alemadi AO, Al-Sheraim AS, Al-Maadid MA, et al. Examining depression, antidepressants use, and class and their potential associations with osteoporosis and fractures in adult women: Results from ten NHANES cohorts. J Affect Disord. 2025 Jan 15;369:1223-32.
• Sundaresh V, Singh B. Antidepressants and Fracture Risk: Is There a Real Connection? J Am Geriatr Soc. 2020 Sep;68(9):2141-2.
• Tamblyn R, Girard N, Habib B, Iqbal U. Reply to: Antidepressants and Fracture Risk: Is There a Real Connection? J Am Geriatr Soc. 2020 Sep;68(9):2142-3.
• Li Z, Yang C, Wang J, Zheng K, Luo W. The application of CGF combined with GBR in alveolar bone increment for patients with anxiety disorder: A rare case report and literature review. Medicine (Baltimore). 2023 Nov 10;102(45):e35905.
• Ak E, Bulut SD, Bulut S, Akdag HA, Oter GB, Kaya H, et al. Evaluation of the effect of selective serotonin reuptake inhibitors on bone mineral density: an observational cross-sectional study. Osteoporos Int. 2015 Jan;26(1):273-9.
• Hafizi S, Lix LM, Hans D, Bolton JM, Leslie WD. Association of mental disorders and psychotropic medications with bone texture as measured with trabecular bone score. Bone. 2022 Dec;165:116565.
• Larsson B, Mellstrom D, Johansson L, Nilsson AG, Lorentzon M, Sundh D. Normal Bone Microstructure and Density But Worse Physical Function in Older Women Treated with Selective Serotonin Reuptake Inhibitors, a Cross- Sectional Population-Based Study. Calcif Tissue Int. 2018 Sep;103(3):278-88.
• Gupta B, Acharya A, Singh S, Brazzoli S, Ghorab M, Malik S, et al. Evaluation of jawbone morphology and bone density indices in panoramic radiographs of selective serotonin reuptake inhibitor users: a preliminary study. Dentomaxillofac Radiol. 2019 Jan;48(1):20170360.
• Mirhashemi AH, Ahmad Akhoundi MS, Sheikhzadeh S, Momeni N, Dehpour A, Alaeddini M, et al. Effect of Fluoxetine Consumption on Orthodontic Tooth Movement in Rats. J Dent (Tehran). 2015 Dec;12(12):882-9.
• Cavalli A, De Vincentis A, Pedone C, Laudisio A, Santoro L, Ferrara MC, et al. Deprescribing psychoactive drugs in older orthogeriatric patients: findings from the GIOG2.0 Italian survey. BMC Geriatr. 2025 Mar 1;25(1):138.
• Hughes GA, Inacio MC, Rowett D, Caughey GE, Air T, Lang CE, et al. Risk of adverse outcomes associated with mirtazapine compared to sertraline use among older people living in long-term care facilities. Age Ageing. 2025 Mar 28;54(4).
• Carriere I, Farre A, Norton J, Wyart M, Tzourio C, Noize P, et al. Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort. Osteoporos Int. 2016 Nov;27(11):3187-95.
• Misra M, Le Clair M, Mendes N, Miller KK, Lawson E, Meenaghan E, et al. Use of SSRIs may Impact Bone Density in Adolescent and Young Women with Anorexia Nervosa. CNS Spectr. 2010 Sep;15(9):579-86.
• Marcum ZA, Perera S, Thorpe JM, Switzer GE, Castle NG, Strotmeyer ES, et al. Antidepressant Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study. Ann Pharmacother. 2016 Jul;50(7):525-33.
• Saluan QN, Bauer GR, Vyas H, Mohi A, Durham EL, Cray JJ, Jr. Selective serotonin re-uptake inhibitors affect craniofacial structures in a mouse model. PLoS One. 2024;19(7):e0307134.
• Qiu S, Divine G, Warner E, Rao SD. Reference Intervals for Bone Histomorphometric Measurements Based on Data from Healthy Premenopausal Women. Calcif Tissue Int. 2020 Dec;107(6):543-50.
• Al Hezaimi K, Rotstein I, Katz J, Nevins M, Nevins M. Effect of Selective Serotonin Reuptake Inhibitor (Paroxetine) on Newly Formed Bone Volume: Real-Time In Vivo Micro-computed Tomographic Analysis. J Endod. 2023 Nov;49(11):1495-500.
• Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K. Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. Biochim Biophys Acta Mol Basis Dis. 2019 Nov 1;1865(11):165528.
• Elgohary HH, Kamal MM, Rizk SM, Maurice NW. The Expression Profile of the RANK/RANKL/OPG Pathway in Breast Cancer Stem Cells Isolated From Breast Cancer Cell Lines. J Cell Biochem. 2025 Apr;126(4):e70028.
• Zhang S, Chen L, Zhang C, Gong C, He X, Zhong H, et al. Osteoking exerts pro‑osteogenic and anti‑adipogenic effects in promoting bone fracture healing via EGF/EGFR/HDAC1/Wnt/beta‑catenin signaling. Int J Mol Med. 2025 May;55(5).
• Hu L, Chen W, Qian A, Li YP. Wnt/beta-catenin signaling components and mechanisms in bone formation, homeostasis, and disease. Bone Res. 2024 Jul 10;12(1):39.
• Menendez SG, Manucha W. Vitamin D as a Modulator of Neuroinflammation: Implications for Brain Health. Curr Pharm Des. 2024;30(5):323-32.
• Han H, Kang B, Sharker SM, Kashem TB, Kim Y, Lee J, et al. Synergistic effect of ROS-generating polydopamine on drug-induced bone tissue regeneration. Nanoscale. 2024 Nov 7;16(43):20118-30.
• Fink HA, Kuskowski MA, Marshall LM. Association of stressful life events with incident falls and fractures in older men: the Osteoporotic Fractures in Men (MrOS) Study. Age Ageing. 2014 Jan;43(1):103-8.
• Feuer AJ, Demmer RT, Thai A, Vogiatzi MG. Use of selective serotonin reuptake inhibitors and bone mass in adolescents: An NHANES study. Bone. 2015 Sep;78:28-33.
• Sreeja V, Jose A, Patel S, Menon B, Athira KV, Chakravarty S. Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach. Neurochem Int. 2024 Feb;173:105672.
• Sanwalka N, Khadilkar A, Chiplonkar S, Khatod K, Phadke N, Khadilkar V. Influence of Vitamin D Receptor Gene Fok1 Polymorphism on Bone Mass Accrual Post Calcium and Vitamin D Supplementation. Indian J Pediatr. 2015 Nov;82(11):985-90.
• Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone. 2010 Jan;46(1):13-7.
• Owrang M, Noorafshan A, Rafati A, Karbalay-Doust S. The effects of curcumin and sertraline on stress-induced changes in the stomach tissues of rats. Naunyn Schmiedebergs Arch Pharmacol. 2023 Sep;396(9):2057-69.
• Hodge JM, Wang Y, Berk M, Collier FM, Fernandes TJ, Constable MJ, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013 Jul 1;74(1):32-9.
• Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int. 2012 Jan;23(1):365-75.
• Rauma PH, Honkanen RJ, Williams LJ, Tuppurainen MT, Kroger HP, Koivumaa-Honkanen H. Effects of antidepressants on postmenopausal bone loss - A 5-year longitudinal study from the OSTPRE cohort. Bone. 2016 Aug;89:25-31.
• Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008 Mar;23(2):84-7.
• Sheftel CM, Sartori LC, Hunt ER, Manuel RSJ, Bell AM, Domingues RR, et al. Peripartal treatment with low-dose sertraline accelerates mammary gland involution and has minimal effects on maternal and offspring bone. Physiol Rep. 2022 Mar;10(5):e15204.
• Kahl KG, Rudolf S, Stoeckelhuber BM, Dibbelt L, Gehl HB, Markhof K, et al. Bone mineral density, markers of bone turnover, and cytokines in young women with borderline personality disorder with and without comorbid major depressive disorder. Am J Psychiatry. 2005 Jan;162(1):168-74.
• Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int. 2008 Jan;19(1):1-12.
• Quiarato Lozano AF, Marques Tavares B, Villela ESP, Franco de Barros JW, De Grava Kempinas W. Reproductive Development of Male Rats Exposed In Utero to Stress and/or Sertraline. Toxicol Sci. 2022 Nov 23;190(2):189-203.
• Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008 Aug;28(4):411-7.